The CLOTS 3 trial was set up to test whether Intermittent Pneumatic Compression (IPC for short) reduces patients' risks of developing a blood clot (Deep Vein Thrombosis –DVT) in the veins of the leg after being hospitalised with a stroke.

The IPC was Kendall™ SCD Express Sequential Compression System
- Thigh-length
- Sequential & circumferential compression
- Venous refill technology
- Original & Comfort sleeves were used in the trial.

These were applied day & night, for up to 30 days till patients were discharged, dead or mobile.

Patients had an ultrasound scan of their legs at 7-10 days, and 25-30 days to screen for DVTs. There was excellent balance for all baseline variables & post enrolment anti-thrombotic medication.

The risk of proximal DVT was 8.5% in those receiving IPC, and 12.1% in those receiving routine care only – a reduction of about 1/3. In addition patients treated with IPC were more likely to survive till 6 months.

The Conclusions from the trial are:
- IPC is feasible and safe
- IPC is an effective form of VTE prophylaxis NNT = 28 for proximal DVT
- It probably improves overall survival NNT = 43 for death in 30 days
- Effective in ischaemic & haemorrhagic stroke

These results have been published in the Lancet (www.clotstrial.com). On the basis of these results we expect those responsible for developing guidelines for stroke to recommend that IPC should be routinely available to immobile stroke patients in hospital. This would apply to perhaps 60,000 patients each year in the UK.

Thanks to:
- Patients and their families
- All our collaborators
- Coordinating team in Edinburgh
- Members of UK Stroke Research Network
- Funders

This project was funded by the National Institute for Health Research Health Technology Assessment (HTA) Programme (project number 08/14/03) and will be published in full in Health Technology Assessment.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NHS, NIHR or the Department of Health.